Jinling Pharmaceutical Co Ltd (000919) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has a cash flow conversion efficiency ratio of 0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.01 Million ≈ $10.83 Million USD) by net assets (CN¥4.85 Billion ≈ $709.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jinling Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Jinling Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Jinling Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Jinling Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Transcat Inc
NASDAQ:TRNS
|
0.041x |
|
Zhang Xiaoquan Inc.
SHE:301055
|
N/A |
|
Samsung Electro Mechanics Pref
KO:009155
|
0.030x |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D
IS:KRDMD
|
0.031x |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
0.063x |
|
MTY Food Group Inc
TO:MTY
|
0.048x |
|
Advanced Nano Products Co. Ltd
KQ:121600
|
0.027x |
|
Arvinas Inc
NASDAQ:ARVN
|
-0.070x |
Annual Cash Flow Conversion Efficiency for Jinling Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual cash flow conversion efficiency of Jinling Pharmaceutical Co Ltd from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see 000919 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.85 Billion ≈ $709.50 Million |
CN¥154.19 Million ≈ $22.56 Million |
0.032x | -26.26% |
| 2023-12-31 | CN¥3.68 Billion ≈ $539.22 Million |
CN¥158.92 Million ≈ $23.26 Million |
0.043x | -39.97% |
| 2022-12-31 | CN¥3.63 Billion ≈ $530.75 Million |
CN¥260.59 Million ≈ $38.13 Million |
0.072x | -13.04% |
| 2021-12-31 | CN¥3.53 Billion ≈ $517.22 Million |
CN¥292.03 Million ≈ $42.73 Million |
0.083x | -8.93% |
| 2020-12-31 | CN¥3.43 Billion ≈ $502.38 Million |
CN¥311.46 Million ≈ $45.58 Million |
0.091x | -33.30% |
| 2019-12-31 | CN¥3.42 Billion ≈ $501.14 Million |
CN¥465.85 Million ≈ $68.17 Million |
0.136x | +1.78% |
| 2018-12-31 | CN¥3.25 Billion ≈ $475.00 Million |
CN¥433.83 Million ≈ $63.48 Million |
0.134x | -7.89% |
| 2017-12-31 | CN¥3.05 Billion ≈ $446.88 Million |
CN¥443.11 Million ≈ $64.84 Million |
0.145x | +360.72% |
| 2016-12-31 | CN¥3.05 Billion ≈ $446.75 Million |
CN¥96.15 Million ≈ $14.07 Million |
0.031x | -56.65% |
| 2015-12-31 | CN¥2.92 Billion ≈ $427.95 Million |
CN¥212.45 Million ≈ $31.09 Million |
0.073x | -33.36% |
| 2014-12-31 | CN¥2.75 Billion ≈ $402.55 Million |
CN¥299.89 Million ≈ $43.88 Million |
0.109x | +3.48% |
| 2013-12-31 | CN¥2.57 Billion ≈ $376.72 Million |
CN¥271.21 Million ≈ $39.69 Million |
0.105x | +11.91% |
| 2012-12-31 | CN¥2.47 Billion ≈ $360.82 Million |
CN¥232.12 Million ≈ $33.97 Million |
0.094x | +26.66% |
| 2011-12-31 | CN¥2.33 Billion ≈ $340.26 Million |
CN¥172.82 Million ≈ $25.29 Million |
0.074x | -8.07% |
| 2010-12-31 | CN¥2.20 Billion ≈ $321.83 Million |
CN¥177.81 Million ≈ $26.02 Million |
0.081x | -11.82% |
| 2009-12-31 | CN¥2.05 Billion ≈ $300.70 Million |
CN¥188.41 Million ≈ $27.57 Million |
0.092x | -43.58% |
| 2008-12-31 | CN¥1.88 Billion ≈ $274.89 Million |
CN¥305.26 Million ≈ $44.67 Million |
0.162x | +168.31% |
| 2007-12-31 | CN¥1.95 Billion ≈ $285.26 Million |
CN¥118.06 Million ≈ $17.28 Million |
0.061x | -25.72% |
| 2006-12-31 | CN¥1.70 Billion ≈ $248.57 Million |
CN¥138.50 Million ≈ $20.27 Million |
0.082x | +16.56% |
| 2005-12-31 | CN¥1.56 Billion ≈ $228.64 Million |
CN¥109.29 Million ≈ $15.99 Million |
0.070x | -35.69% |
| 2004-12-31 | CN¥1.47 Billion ≈ $214.99 Million |
CN¥159.81 Million ≈ $23.38 Million |
0.109x | -7.32% |
| 2003-12-31 | CN¥1.38 Billion ≈ $201.81 Million |
CN¥161.86 Million ≈ $23.69 Million |
0.117x | +11.72% |
| 2002-12-31 | CN¥1.24 Billion ≈ $181.58 Million |
CN¥130.36 Million ≈ $19.08 Million |
0.105x | +26.04% |
| 2001-12-31 | CN¥1.11 Billion ≈ $162.39 Million |
CN¥92.49 Million ≈ $13.53 Million |
0.083x | -61.78% |
| 2000-12-31 | CN¥1.06 Billion ≈ $155.22 Million |
CN¥231.31 Million ≈ $33.85 Million |
0.218x | +458.19% |
| 1999-12-31 | CN¥1.02 Billion ≈ $148.96 Million |
CN¥39.77 Million ≈ $5.82 Million |
0.039x | -- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more